Humira®

INN: adalimumab

Approved for use in:

Crohn’s Disease (moderate-severe)
Ulcerative Colitis (moderate-severe)

Type/Class

Originator Biologic

Delivery Route

Subcutaneous Injection

Health Canada Approval

2004

Storage

Refrigerate between 2 and 8°C in original package until ready to use, do not freeze, protect from light, syringes must be used within 14 days of first return to room temperature, if not used within that time period the syringe must be discarded.

Use in Older Adults (65+)

May be used, please consult your doctor.

Pregnancy Indication

No pattern of major birth defects has been observed; infants may be at increased risk for infection.

Breastfeeding Indication

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for adalimumab and any potential adverse effects on the breastfed child from adalimumab or from the underlying maternal condition.

Pediatric Indication

Authorized for patients 13-17 years old weighing ≥ 40 kg with severely active Crohn’s disease and patients ≥ 5 years old with moderate to severe active ulcerative colitis.

Learn More

View the Humira® product monograph.